Furthermore, ELK1 is known to be activated by the RAS/RAF/MEK/ERK signaling pathway in breast epithelial cells [48], and RAS activation is one of the mechanisms for EGFR-TKI resistance in lung cancer [49]. This evidence concerns the gene MAP2K7 and lung carcinoma.